Biology | Jotup

XORTX Welcomes New Member to the Board of Directors

Retrieved on:

Monday, April 8, 2024

Abbey, Manager, Biotechnology, Pfizer, Business, Emergent, Patient, Vaccine, Research, Senior, Psychology, Kidney disease, Biology, Johns Hopkins University, Therapy, Industry Dive, Pharmaceutical industry

Abigail “Abbey” L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ: GMDA) and a member of its Board of Directors.

Key Points:

Abigail “Abbey” L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ: GMDA) and a member of its Board of Directors.
Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry delivering life-enhancing therapies from research to commercialization for patients in need.
Anthony Giovinazzo, XORTX’s Chairman of the Board commented, “We are delighted to welcome Abbey to the Board of Directors.
Abbey is a highly skilled and experienced leader who will significantly contribute to the Board of Directors carrying out its mandate.

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

Retrieved on:

Monday, April 8, 2024

HER2, Survival, Biology, NRG1, AACR, Publication, Vaccine

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced preclinical data on zenocutuzumab (Zeno) in cancer models with high neuregulin 1 (NRG1) expression were presented at the American Association of Cancer Research (AACR) Annual Meeting 2024.

Key Points:

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced preclinical data on zenocutuzumab (Zeno) in cancer models with high neuregulin 1 (NRG1) expression were presented at the American Association of Cancer Research (AACR) Annual Meeting 2024.
“Exemplary of our approach to developing multispecific antibodies, Zeno was selected utilizing unbiased assays to allow biology to teach us which is the best potential Biclonics®.
Thereafter, we continue to learn more both preclinically and mechanistically, to identify where the molecule holds potential,” said Cecile Geuijen, Chief Scientific Officer of Merus.
“In this study, we examined the efficacy of Zeno in preclinical models expressing high NRG1 levels and found evidence of anti-tumor activity in multiple tumor types.”
Zenocutuzumab, a HER2 × HER3 bispecific antibody, is effective in cancer models with high NRG1 expression
Observations in the presentation include:
Zeno was also observed to:
Inhibit proliferation of HCC95, an NRG1-amplified lung cancer cell line, and block signaling through pathways involved in the regulation of cell growth and survival
The full presentation is available on the Publications page of our website.

23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on:

Friday, April 5, 2024

Data also show soluble ULBP6 is a dominant immunosuppressor compared to other soluble NKG2D ligands due to its highest binding affinity to NKG2D among all NKG2D ligands.

Key Points:

Data also show soluble ULBP6 is a dominant immunosuppressor compared to other soluble NKG2D ligands due to its highest binding affinity to NKG2D among all NKG2D ligands.
ULBP6 is a stress-induced ligand that is upregulated on the surface of cancer cells and binds to the activating immunoreceptor NKG2D found on NK and T cells.
The presentations will be available on the 23andMe Investor Relations and Therapeutics websites on April 8, 2024.
Title: 23ME-01473, a novel anti-ULBP6/2/5 monoclonal antibody, reinvigorates anti-tumor NK cell function through NKG2D and FcγRIIIa activation

Leash Biosciences Announces $9.3 Million Seed Financing to Pioneer AI-Driven Medicinal Chemistry

Retrieved on:

Friday, April 5, 2024

Drug design, Biotechnology, Drug discovery, Artificial intelligence, Stripe, Myriad Genetics, Protein folding, Biology, Data collection, Chemistry, Therapy, Machine learning, Data, Leash, Collection

SALT LAKE CITY, April 05, 2024 (GLOBE NEWSWIRE) -- Leash Biosciences, an artificial intelligence and machine learning (AI/ML)-native biotechnology company unleashing machine learning to solve medicinal chemistry, today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection. The oversubscribed round was led by Springtide Ventures with participation from MetaPlanet, Top Harvest Capital, Mitsui Global Investment, MFV Partners, Recursion CEO and co-founder Chris Gibson, and Recursion co-founder Blake Borgeson.

Key Points:

SALT LAKE CITY, April 05, 2024 (GLOBE NEWSWIRE) -- Leash Biosciences, an artificial intelligence and machine learning (AI/ML)-native biotechnology company unleashing machine learning to solve medicinal chemistry, today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection.
To achieve this, Leash is producing bespoke, expansive datasets of protein targets binding to chemicals.
We believe a similar strategy will revolutionize how we approach medicinal chemistry," said Ian Quigley, CEO of Leash Biosciences.
"Leash's platform stands apart with its combined excellence in machine learning, experimental biology, and medicinal chemistry," said Claire Smith, Lead Investor at Springtide Ventures.

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on:

Thursday, April 4, 2024

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points:

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
“We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

Retrieved on:

Thursday, April 4, 2024

Journal, Therapy, Biology, Cancer, AAI

WATERTOWN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the publication of an abstract for an upcoming poster presentation at IMMUNOLOGYTM 2024, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Chicago, Illinois.

Key Points:

WATERTOWN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the publication of an abstract for an upcoming poster presentation at IMMUNOLOGYTM 2024, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Chicago, Illinois.
“We are thrilled to be attending and presenting for the first time at AAI to highlight the data supporting the potential of our novel platform in immunology-based diseases beyond cancer,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf.
“While our core focus remains rooted in oncology, we understand that the biology driving our PREDATOR platform is also capable of targeting immunology targets, and this data validates the potential utility in broader therapeutic areas.
It’s a pivotal moment as we step into the immunology landscape, ready to showcase our innovative contributions and engage with fellow leaders in the field.”
Details for the poster presentation is as follows:

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Retrieved on:

Thursday, April 4, 2024

This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.

Key Points:

This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.
Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.
Research Collaboration: Biognosys and Alamar will embark on a joint research initiative to explore plasma biology.
Oliver Rinner, Ph.D., Founder and CEO of Biognosys, expressed enthusiasm about the collaboration: “We are excited to join forces with Alamar to advance proteomics research.

Dr. Marra Francis Joins Genece Health as Chief Medical Officer

Retrieved on:

Wednesday, April 3, 2024

Health, Obstetrics, Faculty, Gynaecology, Physician, FACOG, DEL, Memorial Hermann–Texas Medical Center, Lung, Breast, University, MD, Biology, Ovary, Cancer, Liquid biopsy, GeneDx, Occidental College

DEL MAR, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Genece Health, a molecular testing company focused on improving cancer detection for lung, breast, ovarian and other cancers, today announced that Marra Francis, MD, FACOG, has joined the company as its chief medical officer.

Key Points:

DEL MAR, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Genece Health, a molecular testing company focused on improving cancer detection for lung, breast, ovarian and other cancers, today announced that Marra Francis, MD, FACOG, has joined the company as its chief medical officer.
Dr. Francis’ past experience also includes serving as head of medical affairs for women's health of Sema4 (now GeneDx); as executive medical director of EverlyWell; and as chief medical officer of Aspira Women's Health.
Dr. Francis holds a medical degree from the University of Connecticut Health Center and a bachelor of arts degree in biology from Occidental College.
“We are delighted to have Marra join our team at a very exciting time for Genece,” said Greg Gosch, CEO of Genece Heath.

Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

Retrieved on:

Wednesday, April 3, 2024

We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.

Key Points:

We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.
In 2023, our focus was also on preparing for a Phase II clinical trial for OATD 01, Molecure's flagship clinical programme.
We are very pleased to report that the first patient has started dosing in a clinical trial at a clinical site in the UK.
The Company plans to obtain further grants for projects within the framework of the pipeline developed so far.

Developing a Dynamic Workforce for Nature-based Climate Solutions and Green Projects in Alberta and British Columbia

Retrieved on:

Tuesday, April 2, 2024

ECO Canada, Government, Growth, Hydrology, Research, Economic development, Policy, Nature, Acquisition, Biology, ECO, Restoration, LE, Workforce, Forestry

CALGARY, Alberta, April 02, 2024 (GLOBE NEWSWIRE) -- ECO Canada, a leading organization dedicated to advancing environmental careers and the environmental workforce, has released its latest research findings on the workforce required for nature-based climate solutions and green infrastructure projects in Alberta and British Columbia.

Key Points:

CALGARY, Alberta, April 02, 2024 (GLOBE NEWSWIRE) -- ECO Canada, a leading organization dedicated to advancing environmental careers and the environmental workforce, has released its latest research findings on the workforce required for nature-based climate solutions and green infrastructure projects in Alberta and British Columbia.
This comprehensive study, titled " Developing a Dynamic Workforce for Nature-based Climate Solutions and Green Infrastructure Projects in Alberta and British Columbia: A Sector Report" provides invaluable insights into the critical roles and skills necessary to support environmental sustainability and economic development.
Nature-based climate solutions and green infrastructure projects play a pivotal role in shaping the environmental sector, influencing policy decisions, technological advancements, and sustainability strategies.
Opportunities to improve talent acquisition and retention strategies to effectively support nature-based climate solutions and green infrastructure projects.